SequelSEC

Definium Therapeutics, Inc. DFTX

Medicinal Chemicals & Botanical Products · CIK 0001813814 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$166.31M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Definium Therapeutics, Inc. (DFTX) reported net income of -$183.79M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Definium Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.

Income

Definium Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$166.31M-$103.92M-$93.87M-$66.33M-$93.85M-$33.03M
Net income-$183.79M-$108.68M-$95.73M-$56.80M-$93.04M-$33.94M
Research & development$117.66M$65.30M$52.12M$36.17M$34.79M$18.63M
Weighted-average diluted sharesshares 89.33Mshares 70.46Mshares 39.16Mshares 30.86Mshares 27.38MUnavailable
Pretax income-$183.79M-$108.68M-$95.73M-$56.80M-$94.19M-$33.94M
Income tax expense$0UnavailableUnavailableUnavailable-$1.16MUnavailable
Diluted EPS$-2.06$-1.54$-2.44$-1.84$-3.40Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$48.64M$38.62M$41.74M$30.16M$59.06M$14.40M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Definium Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$257.84M$273.74M$99.70M$142.14M$133.54M$80.09M
Total assets$440.10M$302.15M$124.54M$169.99M$164.00M$81.52M
Current assets$419.32M$281.62M$103.87M$146.06M$137.22M$81.52M
Total liabilities$107.77M$60.70M$46.41M$19.08M$12.34M$5.65M
Current liabilities$66.70M$38.85M$32.25M$17.89M$10.41M$3.01M
Total equity incl. NCI$332.33M$241.45M$78.13M$150.92M$151.66M$75.87M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$19.92M$19.92M$19.92M$19.92M$19.92M$0
Long-term debt$40.58M$21.85M$14.13MUnavailableUnavailableUnavailable
Accounts payable$5.35M$2.01M$4.14M$2.11M$4.18M$2.02M

Cash flow

Definium Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$131.56M-$79.13M-$64.36M-$50.14M-$45.82M-$23.60M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$151.61M$0UnavailableUnavailable-$297.00KUnavailable
Financing cash flow$267.27M$253.20M$21.85M$59.05M$98.82M$96.70M
Net change in cash-$15.90M$174.04M-$42.44M$8.60M$53.44M$73.39M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Definium Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio6.29x7.25x3.22x8.16x13.18x27.10x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DFTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAWH ADIA AIBT BTMD CBDY CFOO CGC CHUC CRON CYAN FTLF HYEX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.